Based on an incomplete data set and its own understanding of the ulcerative colitis (UC) market, Pfizer Inc. took a bit of a leap of faith in December when it agreed to acquire Arena Pharmaceuticals, Inc. for $6.7bn. But now detailed results from the Phase III ELEVATE UC clinical trials presented at Digestive Disease Week (DDW) on 24 May show that Pfizer’s M&A leap was not a misstep.
Etrasimod Results Justify Pfizer’s Leap Of Faith In Arena Buyout
Big Pharma Executed $6.7bn Deal Without Seeing Phase III Data
Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year.
More from Clinical Trials
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024